search button

piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4

  • Authors:
    • Dan Li
    • Yingquan Luo
    • Yawen Gao
    • Yue Yang
    • Yina Wang
    • Yan Xu
    • Shengyu Tan
    • Yuwei Zhang
    • Juan Duan
    • Yu Yang

  • View Affiliations

  • Published online on: July 11, 2016     https://doi.org/10.3892/ijmm.2016.2671
  • Pages: 927-936
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Piwi-interacting RNAs (piRNAs or piRs) are a novel class of non-coding RNAs that participate in germline development by silencing transposable elements and regulating gene expression. To date, the association between piRNAs and non‑small cell lung carcinoma (NSCLC) has not yet been elucidated. In the present study, we have demonstrated that a significant increase in piR-651 expression occurs in NSCLC. Furthermore, the abnormal expression of piR-651 was associated with cancer progression in the patients with NSCLC. The upregulation of piR-651 in A549 cells caused a significant increase in cell viability and metastasis. The percentage of arrested cells in the G0/G1 phase was lower after piR-651 overexpression compared with the controls. We also examined the expression of oncogenes and cancer suppressor genes following piR-651 overexpression in NSCLC cells. Only the expression levels of cyclin D1 and CDK4 significantly correlated with piR-651 expression both in vivo and in vitro. Furthermore, by injecting nude mice with A549 cells transfected with piR-651 plasmids to establish a xenograft model, we demonstrated that there was a correlation between piR-651 overexpression and tumor growth, which was mediated by cyclin D1 and CDK4. These findings strongly support the notion that piR-651 induces NSCLC progression through the cyclin D1 and CDK4 pathway and it may have applications as a potential diagnostic indicator and therapeutic target in the management of NSCLC.
View Figures
View References

Related Articles

Journal Cover

September-2016
Volume 38 Issue 3

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 5.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
  • CiteScore: 10.7
  • CiteScore Rank: Q1: #35/328 Biochemistry, Genetics and Molecular Biology
  • Source Normalized Impact per Paper (SNIP): 0.994
  • SCImago Journal Rank (SJR): 0.922
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li D, Luo Y, Gao Y, Yang Y, Wang Y, Xu Y, Tan S, Zhang Y, Duan J, Yang Y, Yang Y, et al: piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4. Int J Mol Med 38: 927-936, 2016
APA
Li, D., Luo, Y., Gao, Y., Yang, Y., Wang, Y., Xu, Y. ... Yang, Y. (2016). piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4. International Journal of Molecular Medicine, 38, 927-936. https://doi.org/10.3892/ijmm.2016.2671
MLA
Li, D., Luo, Y., Gao, Y., Yang, Y., Wang, Y., Xu, Y., Tan, S., Zhang, Y., Duan, J., Yang, Y."piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4". International Journal of Molecular Medicine 38.3 (2016): 927-936.
Chicago
Li, D., Luo, Y., Gao, Y., Yang, Y., Wang, Y., Xu, Y., Tan, S., Zhang, Y., Duan, J., Yang, Y."piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4". International Journal of Molecular Medicine 38, no. 3 (2016): 927-936. https://doi.org/10.3892/ijmm.2016.2671